Literature DB >> 21914553

Tropisetron upregulates cannabinoid CB1 receptors in cerebellar granule cells: possible involvement of calcineurin.

Reza Rahimian1, Ahmad Reza Dehpour, Gohar Fakhfouri, Mohammad Reza Khorramizadeh, Jean-Eric Ghia, Mohammad Seyedabadi, Antonio Caldarelli, Kazem Mousavizadeh, Mehdi Forouzandeh, Shahram Ejtemaei Mehr.   

Abstract

Tropisetron, a selective 5-HT(3) receptor antagonist, is widely used to counteract chemotherapy-induced emesis. Some investigations describe disparate effects including immunomodulatory properties for tropisetron which may be mediated through immunophilin-calcineurin pathway. Calcineurin, a phosphatase involved in immune system signaling, modulates expression of several genes, such as Cannabinoid type one (CB(1)) receptors. On the quest for its underlying mechanisms of action, this study aimed to investigate the effect of tropisetron on calcineurin activity and CB(1) receptor expression and function in cerebellar granule neurons (CGNs). The rat pup CGNs were used as highly calcineurin-rich and devoid of 5-HT(3) receptor neuronal cells. Calcineurin activity was assessed in CGNs treated with tropisetron or the congener granisetron at 1nM-10μM concentrations. Moreover, cannabinoid CB(1) receptor expression at mRNA and protein levels were investigated by real time PCR and western blotting, respectively and its functionality studied by measuring the secondary messenger cAMP in CGNs receiving tropisetron or granisetron. Results indicate that tropisetron, but not granisetron, significantly inhibits the phosphatase activity of calcineurin, over-expresses the CB(1) receptors at both transcriptional and protein levels, and reduces cAMP content. Our investigation shows that tropisetron targets calcineurin in a receptor-independent fashion. Tropisetron-induced CB(1) receptor up-regulation might underlie many pharmacological aspects of tropisetron unrelated to anti-emesis.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21914553     DOI: 10.1016/j.brainres.2011.08.050

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  6 in total

1.  Granisetron Alleviates Alzheimer's Disease Pathology in TgSwDI Mice Through Calmodulin-Dependent Protein Kinase II/cAMP-Response Element Binding Protein Pathway.

Authors:  Sweilem B Al Rihani; Renny S Lan; Amal Kaddoumi
Journal:  J Alzheimers Dis       Date:  2019       Impact factor: 4.472

Review 2.  From Chemotherapy-Induced Emesis to Neuroprotection: Therapeutic Opportunities for 5-HT3 Receptor Antagonists.

Authors:  Gohar Fakhfouri; Kazem Mousavizadeh; Sharam Ejtemaei Mehr; Ahmad Reza Dehpour; Mohammad Reza Zirak; Jean-Eric Ghia; Reza Rahimian
Journal:  Mol Neurobiol       Date:  2014-11-07       Impact factor: 5.590

3.  Phase II clinical trial of palonosetron combined with tropisetron in preventing chemotherapy-induced nausea and vomiting.

Authors:  Yuan Ma; Lei Su; Liyan Liu; Chao Xie; Xia Zhang; Bao Song; Sensen Cheng; Jie Liu
Journal:  Int J Clin Exp Med       Date:  2015-05-15

4.  In vitro effects of tropisetron and granisetron against Echinococcus granulosus (s.s.) protoscoleces by involvement of calcineurin and calmodulin.

Authors:  Mohammad Reza Shiee; Eshrat Beigom Kia; Farzaneh Zahabiun; Mahmood Naderi; Elahe Motevaseli; Shahram Nekoeian; Majid Fasihi Harandi; Ahmad Reza Dehpour
Journal:  Parasit Vectors       Date:  2021-04-12       Impact factor: 3.876

5.  Tropisetron Preconditioning Decreases Myocardial Biomarkers in Patients Undergoing Heart Valve Replacement Surgery.

Authors:  Di Yu; Xingrui Gong; Yufei Zhang; Qing Li; Mazhang Zhang
Journal:  Front Med (Lausanne)       Date:  2022-03-29

6.  The Neuroprotective Effect of Lithium in cannabinoid Dependence is Mediated through Modulation of Cyclic AMP, ERK1/2 and GSK-3β Phosphorylation in Cerebellar Granular Neurons of Rat.

Authors:  Hamid Reza Rahimi; Mohammad Hossein Ghahremani; Ahmad Reza Dehpour; Mohammad Sharifzadeh; Shahram Ejtemaei-Mehr; Ali Razmi; Seyed Nasser Ostad
Journal:  Iran J Pharm Res       Date:  2015       Impact factor: 1.696

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.